Close



Nov 17, 2020 08:31AM
Nov 15, 2020 04:30PM
Nov 11, 2020 08:30AM
Nov 5, 2020 06:59AM
Oct 5, 2020 09:30AM
Oct 5, 2020 06:30AM
Oct 5, 2020 06:30AM Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Aug 31, 2020 06:03AM
Aug 29, 2020 09:30AM
Aug 10, 2020 04:05PM
Aug 4, 2020 04:05PM
Aug 3, 2020 09:52AM
Aug 3, 2020 08:30AM
Aug 3, 2020 08:30AM MyoKardia Doses First Patient in Phase 3 VALOR-HCM Trial of Mavacamten
Jul 23, 2020 04:07PM
Jul 23, 2020 04:05PM
May 11, 2020 09:28AM
May 11, 2020 07:35AM
May 11, 2020 07:30AM
Mar 30, 2020 10:33AM
Mar 30, 2020 10:30AM MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients
Mar 26, 2020 08:33AM
Mar 26, 2020 08:30AM
Nov 11, 2019 07:32AM
Nov 11, 2019 07:30AM
Nov 11, 2019 07:30AM
Sep 10, 2019 08:44AM
Sep 10, 2019 08:44AM MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients
Aug 31, 2019 05:00AM
Apr 30, 2019 08:38AM
Apr 30, 2019 08:30AM
Mar 4, 2019 08:12AM
Mar 4, 2019 08:02AM
Feb 28, 2019 08:30AM
Jan 23, 2019 08:35AM UPDATE: MyoKardia (MYOK) Appoints William Fairey as EVP and Chief Commercial Officer
Jan 23, 2019 08:30AM
Nov 12, 2018 07:33AM
Nov 12, 2018 07:30AM
Oct 24, 2018 04:30PM
Aug 8, 2018 04:02PM
Jun 26, 2018 08:32AM
Jun 26, 2018 08:30AM MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
May 21, 2018 07:34AM
May 21, 2018 07:30AM
May 10, 2018 08:35AM
May 10, 2018 08:30AM
May 8, 2018 04:01PM
Apr 2, 2018 08:35AM
Apr 2, 2018 08:30AM MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
Mar 9, 2018 09:23AM

251,368 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All